Dermata Therapeutics, Inc. — Form 8-K

On August 16, 2026, Dermata Therapeutics (market cap ~$3.1M) sold approximately $3.36M aggregate subscription amount of common stock, pre-funded warrants ($0.001 exercise price, exercisable immediately), Series E common warrants (5-year term, $1.46–$1.47 exercise price), and Series F common warrants (24-month term, $1.46–$1.47 exercise price) to multiple accredited investors under Regulation D Rule 506. Purchasers receive equal treatment, anti-dilution protections, registration rights, and potential liquidated damages for registration delays. The transaction requires stockholder approval for warrant issuance.